UPDATE: Important information about LabCorp's response to COVID-19 Read more >>>

News Release

Printer Friendly Version View printer-friendly version
<< Back
Brian Caveney, Chief Medical Officer and President of LabCorp Diagnostics, Named to Modern Healthcare's 50 Most Influential Clinical Executives List

BURLINGTON, N.C., June 16, 2020 — LabCorp (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, today announced that Dr. Brian Caveney, chief medical officer and president of LabCorp Diagnostics, was recognized by Modern Healthcare as one of this year’s 50 Most Influential Clinical Executives.

The recognition program acknowledges clinicians working in the healthcare industry who are deemed by their peers and an expert panel to be the most influential in terms of demonstrating leadership and impact.

“It’s an honor and a privilege to be recognized by my peers for this distinction from Modern Healthcare,” said Dr. Caveney. “I am extremely proud of LabCorp’s diagnostics and drug development businesses, which have stood ready to address the COVID-19 situation with increased testing capacity, multiple testing options and clinical research on vaccines and therapies. I am also humbled to work alongside my colleagues, who through science, technology, and delivery, are working to address significant, unmet healthcare needs to improve health and improve lives.”

“Healthcare organizations are utilizing their greatest assets as they transform: their former front-line clinicians," said Aurora Aguilar, editor of Modern Healthcare. “Former and practicing physicians and nurses have taken the helms of healthcare providers across the country and improved quality of care, patient satisfaction and margins. Modern Healthcare congratulates the honorees and thanks them for their contributions to patient care.”

Dr. Caveney joined LabCorp after serving as chief medical officer of Blue Cross and Blue Shield of North Carolina (Blue Cross NC). He also served as chief clinical officer of Mosaic Health Solutions, a wholly owned subsidiary of Blue Cross NC for strategic investments in diversified health solutions. Prior to Blue Cross NC, Dr. Caveney was a practicing physician and assistant professor at Duke University Medical Center.

The complete ranking is featured in the June 15 issue of Modern Healthcare, and profiles of the honorees are available at ModernHealthcare.com/50MostInfluential.

About LabCorp
LabCorp (NYSE: LH), an S&P 500 company, is a leading global life sciences company that is deeply integrated in guiding patient care, providing comprehensive clinical laboratory and end-to-end drug development services. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostics solutions, brings innovative medicines to patients faster, and uses technology to improve the delivery of care. LabCorp reported revenue of more than $11.5 billion in 2019.

To learn more about LabCorp, visit www.LabCorp.com, and to learn more about LabCorp’s Covance drug development business, visit www.Covance.com.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, including but not limited to statements with respect to recognition and reputation of the Company. Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the Company’s control, including without limitation, the COVID-19 pandemic and its impact on our business and financial condition as well as general economic, business, and market conditions, competitive actions and other unforeseen changes and general uncertainties in the marketplace, changes in government regulations, including healthcare reform, customer purchasing decisions, including changes in payer regulations or policies, other adverse actions of governmental and third-party payers, changes in testing guidelines or recommendations, federal, state, and local governmental responses to the COVID-19 pandemic, the effect of public opinion on the Company’s reputation, adverse results in material litigation matters, failure to maintain or develop customer relationships, our ability to develop or acquire new products and adapt to technological changes, failure in information technology, systems or data security, the number of revenue days in a financial period, personnel costs, and the effect of exchange rate fluctuations, and employee relations. These factors, in some cases, have affected and in the future (together with other factors) could affect the Company’s ability to implement the Company’s business strategy and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the Company’s most recent Annual Report on Form 10-K and subsequent Forms 10-Q, including in each case under the heading RISK FACTORS, and in the Company’s other filings with the SEC.

#

LabCorp Contacts:
Media: Pattie Kushner — 336-436-8263
Media@LabCorp.com

Investors: Clarissa Willett — 336-436-5076
Investor@LabCorp.com